Lots of interesting abstracts and cases were submitted for TCTAP 2022. Below are the accepted ones after a thorough review by our official reviewers. Don’t miss the opportunity to expand your knowledge and interact with authors as well as virtual participants by sharing your opinion in the comment section!
TCTAP A-084
Short-Term Efficacy and Safety Outcome of Standalone Balloon Aortic Valvuloplasty: Registry From Thammasat Heart Center, Thailand
By Nattaporn Sangrutaikan, Kid Bhumimuang, Pisit Hutayanon, Muenpetch Muenkaew
Presenter
Nattaporn Sangrutaikan
Authors
Nattaporn Sangrutaikan1, Kid Bhumimuang1, Pisit Hutayanon1, Muenpetch Muenkaew1
Affiliation
Thammasat University Hospital, Thailand1
View Study Report
TCTAP A-084
Valvular Intervention: Aortic
Short-Term Efficacy and Safety Outcome of Standalone Balloon Aortic Valvuloplasty: Registry From Thammasat Heart Center, Thailand
Nattaporn Sangrutaikan1, Kid Bhumimuang1, Pisit Hutayanon1, Muenpetch Muenkaew1
Thammasat University Hospital, Thailand1
Background
Background: Severe aortic stenosis (AS) is one of the common and serious valvular problems. Standard treatment for symptomatic severe AS is surgical aortic valve replacement (SAVR) or Transcatheter aortic valve implantation (TAVI). Balloon aortic valvuloplasty (BAV) has been used as a bridge decision, rescue therapy, bridge to major non-cardiac surgery and palliative therapy. However, in Thailand, there are scant data in term of feasibility and the outcomes of BAV.
Methods
Methods: Consecutive symptomatic severe AS patients who underwent BAV at Thammasat University Hospital between June 2018 and August 2021 were identified. Patient’s characteristics, echocardiographic parameters, procedural data, hemodynamic parameters pre and post BAV were collected. We evaluate success rate of BAV, peri-procedural and post BAV complications, and 30-day all-cause mortality after BAV.
Results
Results: Of 26 patients underwent BAV, mean age was 80.96 ± 10.69 year. The median STS score was 5.44 and 14 patients (53.8%) were in NYHA class 3. Indications were bridging procedure (bridging to SAVR/TAVI, bridging to non-cardiac surgery, bridging to decision) 73.1%, cardiogenic shock 11.5% and palliative therapy 15.4% respectively. Success rate was 84.6%. The mean pressure gradient reduced from 50.56 ± 22.64mmHg to 38.74 ± 17.17mmHg and AVA increased from 0.55 ± 0.18 cm2 to 0.78 ± 0.30 cm2. Peri-procedural complications was 19.23% (n=5) including vascular complications (n=1), arrhythmia (n=2), blood transfusion (n=1), cardiogenic shock (n=1) and infection (UTI; n=1). Intraprocedural mortality was 3.85% (n=1) and 30-day all-cause mortality was 15.38% (n=4). The 3-month survival from death and heart failure was 80.77% (n=21).
Conclusion
Conclusions: Our registry showed the feasibility, efficacy and safety outcomes of BAV in symptomatic severe AS patients. And 3-month survival from CV event were acceptable.